Home

Charles River Associates (CRA) Expands Its Life Sciences Practice

via Business Wire

Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that Phoebe Ng and Chris Nüesch have joined CRA as Vice Presidents in the Life Sciences Practice.

“We are pleased to welcome Phoebe and Chris to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “They are seasoned professionals with a proven track record of navigating complex challenges in areas ranging from portfolio strategy and product development to commercialization, market access, and brand growth.”

“Phoebe and Chris share CRA’s data-driven approach and expertise in achieving meaningful outcomes for CRA’s Life Sciences clients and we look forward to working with them,” said Dr. Gregory K. Bell, Group Vice President and Life Sciences Practice Leader. “Phoebe brings extensive experience across multiple therapeutic areas, with a strong track record of aligning long-term strategic objectives with portfolio sustainability. Chris brings deep expertise in addressing client questions in the specialty disease space, particularly in developing and executing brand and marketing strategies. Their insights will strengthen our ability to support clients in navigating a rapidly evolving healthcare environment.”

Prior to joining CRA, Ms. Ng worked for 23 years at one of the world’s largest pharmaceutical and biotechnology companies, rising to the position of head of new business development in global commercial strategy for cardiovascular, renal, obesity, fibrosis, and pulmonary products. Her responsibilities included pipeline prioritization and expansion, innovation strategies, and commercial investment decisions.

Ms. Ng has a BSc in Medical Science from King’s College London and an MBA from the University of Leicester School of Business.

Prior to joining CRA, Mr. Nüesch held a series of progressively senior roles at industry-leading life sciences strategy consulting firms. He previously served as a partner at a global management consulting firm focused on the life sciences sector. Prior to that, he was a senior director at a healthcare and life sciences consultancy, where he specialized in market access, pricing, and reimbursement strategy.

Mr. Nüesch holds a BS in Biology from the University of Pennsylvania, an MA in Biology from Columbia University, and an MBA in Finance from the NYU Stern School of Business.

About CRA’s Life Sciences Practice

CRA’s Life Sciences Practice works with leading biotech, medical device, and pharmaceutical companies; law firms; regulatory agencies; and national and international industry associations. We provide the analytical expertise and industry experience needed to address our clients’ toughest issues. We have a reputation for rigorous and innovative analysis, careful attention to detail, and the ability to work effectively as part of a wider team of advisers.

About Charles River Associates (CRA)

Charles River Associates® is a leading global consulting firm specializing in economic, financial, and management consulting services. CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides corporations through critical business strategy and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. Headquartered in Boston, CRA has offices throughout the world. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at www.crai.com. Follow us on LinkedIn, Instagram, and Facebook.

SAFE HARBOR STATEMENT

Statements in this press release concerning the addition of Phoebe Ng and Chris Nüesch and the expansion and strengthening of CRA’s Life Sciences Practice, and any future business and outcomes Ms. Ng and Mr. Nüesch may generate for CRA, are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors that could cause actual performance or results to differ materially from any forward-looking statements made by CRA include, among others: the failure to generate engagements for us; the potential loss of clients; the demand environment; global economic conditions; foreign exchange rate fluctuations; and intense competition. Additional potential factors that could affect our financial results are included in our periodic filings with the Securities and Exchange Commission, including those under the heading “Risk Factors.” We cannot guarantee any future results, levels of activity, performance, or achievement. We undertake no obligation to update any forward-looking statements after the date of this press release, and we do not intend to do so.

Contacts